日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

AZD2171(西地尼布)治疗急性髓系白血病或高危骨髓增生异常综合征患者的II期研究

Mattison, Ryan; Jumonville, Alcee; Flynn, Patrick James; Moreno-Aspitia, Alvaro; Erlichman, Charles; LaPlant, Betsy; Juckett, Mark B

Survivorship care plans: is there buy-in from community oncology providers?

生存期护理计划:社区肿瘤医疗服务提供者是否支持?

Salz, Talya; McCabe, Mary S; Onstad, Erin E; Baxi, Shrujal S; Deming, Richard L; Franco, Regina A; Glenn, Lyn A; Harper, Gregory R; Jumonville, Alcee J 4th; Payne, Roxanne M; Peters, Elissa A; Salner, Andrew L; Schallenkamp, John M; Williams, Sheron R; Yiee, Kevin; Oeffinger, Kevin C

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

组蛋白去乙酰化酶抑制剂贝利司他(PXD101)治疗骨髓增生异常综合征(MDS)的II期研究

Cashen, Amanda; Juckett, Mark; Jumonville, Alcee; Litzow, Mark; Flynn, P J; Eckardt, John; LaPlant, Betsy; Laumann, Kristina; Erlichman, Charles; DiPersio, John

A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study

卡培他滨联合拉帕替尼治疗晚期难治性结直肠腺癌的II期研究:威斯康星肿瘤网络研究

Frank, Daniel; Jumonville, Alcee; Loconte, Noelle K; Schelman, William R; Mulkerin, Daniel; Lubner, Sam; Richter, Katie; Winterle, Natalie; Wims, Mary Beth; Dietrich, Leah; Winkler, J Mitchell; Volk, Michael; Kim, Kyungmann; Holen, Kyle D

A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer

奥沙利铂、5-氟尿嘧啶、亚叶酸钙和高剂量卡培他滨治疗转移性结直肠癌患者的II期研究

Lubner, Sam J; Loconte, Noelle K; Holen, Kyle D; Schelman, William; Thomas, James P; Jumonville, Alcee; Eickhoff, Jens C; Seo, Songwon; Mulkerin, Daniel L